Viridian Therapeutics, Inc., a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application $(BLA.AU)$ for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease (TED), in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.